TA no.79 DSC Measurement of Pharmaceuticals 2007.9
-Crystal polymorphism and crystallinity -
In this brief, we measure Carbamazepine, an an-
Differential scanning calorimetry (DSC) has been
tiepileptic drug, and ursodeoxycholic acid, a chol-
added as a general testing method to the Japanese
eretic drug, to ascertain the differences of crystal
Pharmacopoeia and is widely used to evaluate the
thermophysical properties of pharmaceuticals.
It is known that the organic compounds that com-
pose pharmaceuticals can have different crystalline
In one measurement, Carbamazepine, which has
forms or different crystallinity due to refinement or
different crystalline forms (Form I and III), and its
milling. It is very important to clearly identify these
hydrate were measured. In another measurement,
differences when developing pharmaceuticals be-
ursodeoxycholic acid was measured under three
cause crystal polymorphs and crystallinity influence
different milling conditions (no milling, milled 5 min,
medicinal effects and formulation stability. Crystal
polymorphism and crystallinity are influenced by
The measurements were performed using the
temperature change so DSC is indispensable in un-
DSC6220 differential scanning calorimeter.
derstanding the thermophysical properties of phar-
For the measurements, a 2mg sample was heated at
a rate of 10 °C/ min in a nitrogen atmosphere.
Copyright Hitachi High-Tech Science Corporation All rights reserved.
The milled samples showed an exothermic peak at
around 110 °C. The milling process likely broke
Figure 1 shows the DSC results for the three con-
down the crystal structure of the ursodeoxycholic
ditions of Carbamazepine. All samples showed a
acid and changed it to an amorphous form, which was
sharp endothermic peak at around 190 °C. From
the Form III results, we can see that there was
The longer the sample was milled, the larger the
exothermic peak. The longer milling time likely in-
The Form I sample showed an endothermic and an
creased the proportion of the amorphous elements.
exothermic peak between 170 °C and 180 °C. The
crystal structure of Form I crystals melts and then
DSC was used to measure the pharmaceuticals
recrystallizes into the stable Form III.
Carbamazepine and ursodeoxycholic acid. The re-
The hydrate sample showed an endothermic peak
sults confirmed the presence of crystal polymorphism
due to crystal water desorption at around 80 °C.
in Carbamazepine, as well as the polymorphic tran-
This sample is likely crystal water adhered to Form
sition temperature. For ursodeoxycholic acid, the
III crystals. After dehydration, the Form III crystals
results confirmed that the influence of milling on
crystallinity is dependent on milling time.
Using the measurements described in this brief,
DSC can be used to investigate the processing and
Figure 2 shows the DSC results for the three con-
ditions of ursodeoxycholic acid. All samples showed a sharp endothermic peak around 200 °C, which indicates the melting of ursodeoxycholic acid.
Figure 2. DSC results for ursodeoxycholic acid
Copyright Hitachi High-Tech Science Corporation All rights reserved.
267171 INfluenza vaccine and Human Papilloma VIrus vaccines given November 10 about 11:45 AM. Patient woke up with numbness on right side of face on November 11. Presented to Emergency Room on November 12 with Bells Palsy of right side of face. Unable to move right side of face. Unable to close right eye. Previously healthy, no symptoms on day of vaccine administration. Received MR from pediatrici